Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email
I agree to receive
the R3i newsletter

RECENT PUBLICATIONS ON RESIDUAL RISK

2018

Targeting triglycerides: therapeutic potential of ANGPTL3 and apoC-III?

This timely review has highlighted the potential of therapeutic approaches targeting angiopoietin-like protein 3 (ANGPTL3) and apolipoprotein C-III (apoC-III) to reduce triglyceride-rich lipoproteins and related residual cardiovascular risk. Ongoing research has led to new biologicals that suppress the expression or inhibit the function of these two key proteins. These include human monoclonal antibodies or antisense oligonucleotides. This article reviews the mechanisms of action of ANGPTL3 and apoC-III, and why intervening against these targets may offer future promise for reduction in residual cardiovascular risk.
New medications targeting triglyceride-rich lipoproteins: Can inhibition of ANGPTL3 or apoC-III reduce the residual cardiovascular risk?

Olkkonen VM, Sinisalo J, Jauhiainen M.